Abstract
Background: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ulcerative colitis. Aims: To investigate dose optimization in ulcerative colitis patients with secondary loss of response. Methods: This was a retrospective multicentre study. Primary outcome was rapid clinical response assessed at the next administration of infliximab after dose intensification. Secondary outcomes were rapid clinical remission, and clinical response, remission and colectomy rate by week 52. Doubling the dose (10. mg/kg q8 weeks) vs. shortening the dose interval (5. mg/kg every 6 or 4 weeks) were compared. Results: Forty-one patients from eight centres were enrolled (15 for double dose and 26 for interval shortening). Rapid response was achieved in 37/41 patients (90.2%), while 19/41 (46.3%) achieved rapid clinical remission. At week 52, 28/41 patients were maintained in clinical remission, but 4 (9.8%) underwent colectomy. No difference was found between the two optimization strategies. Subjects achieving rapid clinical response had a significantly higher colectomy-free rate at week 52 (p= 0.002). Conclusion: Dose optimization of infliximab was effective to restore clinical response or remission and to prevent colectomy in ulcerative colitis patients with secondary loss of response.
| Original language | English |
|---|---|
| Pages (from-to) | 135-139 |
| Number of pages | 5 |
| Journal | Digestive and Liver Disease |
| Volume | 46 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2014 |
Fingerprint
Keywords
- Dose optimization
- Infliximab
- Loss of response
- Ulcerative colitis
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
Dose optimization is effective in ulcerative colitis patients losing response to infliximab : A collaborative multicentre retrospective study. / Cesarini, Monica; Katsanos, Konstantinos; Papamichael, Konstantinos; Ellul, Pierre; Lakatos, Peter L.; Caprioli, Flavio; Kopylov, Uri; Tsianos, Epameinondas; Mantzaris, Gerassimos J.; Ben-Horin, Shomron; Danese, Silvio; Fiorino, Gionata.
In: Digestive and Liver Disease, Vol. 46, No. 2, 02.2014, p. 135-139.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dose optimization is effective in ulcerative colitis patients losing response to infliximab
T2 - A collaborative multicentre retrospective study
AU - Cesarini, Monica
AU - Katsanos, Konstantinos
AU - Papamichael, Konstantinos
AU - Ellul, Pierre
AU - Lakatos, Peter L.
AU - Caprioli, Flavio
AU - Kopylov, Uri
AU - Tsianos, Epameinondas
AU - Mantzaris, Gerassimos J.
AU - Ben-Horin, Shomron
AU - Danese, Silvio
AU - Fiorino, Gionata
PY - 2014/2
Y1 - 2014/2
N2 - Background: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ulcerative colitis. Aims: To investigate dose optimization in ulcerative colitis patients with secondary loss of response. Methods: This was a retrospective multicentre study. Primary outcome was rapid clinical response assessed at the next administration of infliximab after dose intensification. Secondary outcomes were rapid clinical remission, and clinical response, remission and colectomy rate by week 52. Doubling the dose (10. mg/kg q8 weeks) vs. shortening the dose interval (5. mg/kg every 6 or 4 weeks) were compared. Results: Forty-one patients from eight centres were enrolled (15 for double dose and 26 for interval shortening). Rapid response was achieved in 37/41 patients (90.2%), while 19/41 (46.3%) achieved rapid clinical remission. At week 52, 28/41 patients were maintained in clinical remission, but 4 (9.8%) underwent colectomy. No difference was found between the two optimization strategies. Subjects achieving rapid clinical response had a significantly higher colectomy-free rate at week 52 (p= 0.002). Conclusion: Dose optimization of infliximab was effective to restore clinical response or remission and to prevent colectomy in ulcerative colitis patients with secondary loss of response.
AB - Background: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ulcerative colitis. Aims: To investigate dose optimization in ulcerative colitis patients with secondary loss of response. Methods: This was a retrospective multicentre study. Primary outcome was rapid clinical response assessed at the next administration of infliximab after dose intensification. Secondary outcomes were rapid clinical remission, and clinical response, remission and colectomy rate by week 52. Doubling the dose (10. mg/kg q8 weeks) vs. shortening the dose interval (5. mg/kg every 6 or 4 weeks) were compared. Results: Forty-one patients from eight centres were enrolled (15 for double dose and 26 for interval shortening). Rapid response was achieved in 37/41 patients (90.2%), while 19/41 (46.3%) achieved rapid clinical remission. At week 52, 28/41 patients were maintained in clinical remission, but 4 (9.8%) underwent colectomy. No difference was found between the two optimization strategies. Subjects achieving rapid clinical response had a significantly higher colectomy-free rate at week 52 (p= 0.002). Conclusion: Dose optimization of infliximab was effective to restore clinical response or remission and to prevent colectomy in ulcerative colitis patients with secondary loss of response.
KW - Dose optimization
KW - Infliximab
KW - Loss of response
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=84893691878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893691878&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2013.10.007
DO - 10.1016/j.dld.2013.10.007
M3 - Article
C2 - 24246151
AN - SCOPUS:84893691878
VL - 46
SP - 135
EP - 139
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 2
ER -